Gilead's Oral Ulcerative Colitis Pill Emvistegrast Meets Main Goal in Phase 2 Trial

GILD said on Monday that its experimental once-daily pill emvistegrast met the main goal of a mid-stage trial in adults with moderately to severely active ulcerative colitis. After 12 weeks, 66% of patients taking the 200 mg dose saw a clinical response, compared with 37% of those on placebo, and 31% achieved clinical remission versus 8% on placebo. STAT described that as a 23% placebo-adjusted clinical remission rate. Remission was a secondary measure; clinical response was the primary endpoint.

Emvistegrast is an oral drug that blocks the alpha4beta7 integrin pathway, a mechanism already validated in inflammatory bowel disease by injected and infused therapies. The Phase 2 SWIFT study randomized 238 patients across three doses and placebo, and Gilead reported endoscopic improvement in 39% of patients on the top dose versus 12% on placebo. Adverse events occurred at similar rates on drug and placebo (36% versus 37%), and none of the serious adverse events were judged related to the drug. The data are being presented as a late-breaker at UEG Week 2026 in Barcelona.

BMO Capital Markets analysts called the result "an incremental positive" for Gilead's inflammation strategy and said it establishes emvistegrast as "a credible oral α4β7 option". A convenient pill in a pathway doctors already trust could appeal to patients who would rather avoid injections, which is the commercial case Gilead is building.

What to watch: Gilead plans to start a Phase 3 monotherapy study in 2027, and maintenance data through Week 52 are still to come. The size of the effect in larger, more treatment-experienced populations, and whether the lower doses add anything, will decide how competitive the drug can be.